Key Highlights

  • Danaher (NYSE:DHR) reported third-quarter adjusted earnings of USD 2.11 per share on Wednesday, October 21, 2026, edging past consensus estimates, as revenue rose 8.5% to USD 6.55 billion.
  • Core growth excluding respiratory testing accelerated to 5.5%, a measure that strips out acquisitions, currency and the seasonal swings of respiratory diagnostics.
  • The company raised its 2026 adjusted EPS guidance to USD 8.57 to USD 8.62, and the shares bounced higher during the session after trading lower before the open.
  • Thermo Fisher Scientific (NYSE:TMO) also beat and raised its outlook on the same morning, adding to signs of steadier demand across the life science tools group.

A Narrow Beat and a Higher Floor

Danaher (NYSE:DHR), a life sciences and diagnostics group whose businesses include bioprocessing supplier Cytiva and molecular testing company Cepheid, reported third-quarter results before the open on Wednesday, October 21, 2026. Adjusted EPS was USD 2.11, edging past consensus estimates. Revenue rose 8.5% to USD 6.55 billion. Core growth excluding respiratory testing accelerated to 5.5%. Danaher raised its 2026 adjusted EPS guidance to USD 8.57 to USD 8.62. The shares traded lower before the open, then bounced higher during the regular session, on a day when the S&P 500 rose 0.58%. On the earnings call, the new chief executive set out a goal of clear market share gains. Thermo Fisher Scientific (NYSE:TMO) reported revenue of USD 12.14 billion and raised its outlook the same morning.

Why Core Growth Matters More Than the EPS Beat

For Danaher (NYSE:DHR), core growth is the number that sets the valuation, because the EPS beat was narrow. Core growth removes acquisitions and currency, and excluding respiratory testing also removes demand that rises and falls with flu and COVID seasons. An acceleration to 5.5% on that basis points to steadier underlying orders. A large part of the group is bioprocessing, which sells filters, resins and media that drugmakers consume as they produce biologic medicines, so revenue recurs with production volumes. The gap between 8.5% reported growth and 5.5% core growth reflects currency, acquisitions and the respiratory line. The raised EPS range of USD 8.57 to USD 8.62 gives a higher floor, and the bounce suggests investors focused on that floor rather than the size of the beat.

Risks and What to Watch

The first risk for Danaher (NYSE:DHR) is that core growth of 5.5% reflects customer restocking rather than sustained demand, since bioprocessing orders can swing with inventory levels at drugmakers. The second is respiratory testing, which depends on the severity of the coming flu season and can move fourth-quarter revenue either way. The third is execution under new leadership, since a share-gain goal raises expectations for coming quarters. Rates also matter, with the federal funds range at 3.75% to 4.00%, which tightens funding for biotechnology customers. Investors should watch the Fed decision on Wednesday, October 28, 2026, the midterm elections on Tuesday, November 3, 2026 and fourth-quarter EPS against the raised range.

Where Things Stand

The answer is that Danaher (NYSE:DHR) bounced because core growth excluding respiratory testing accelerated to 5.5% and full-year EPS guidance rose to USD 8.57 to USD 8.62, which outweighed a narrow beat at USD 2.11. A beat and raise from Thermo Fisher on the same day reinforced the read. The next catalysts are the Fed decision on October 28, the midterm elections on November 3 and the respiratory season. Guidance is a company forecast, not a guarantee, and this is not investment advice.